UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data

Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best biotech stocks to buy. UBS reaffirmed its 307 price target and Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) on September 23 in response to MBX’s clinical study for the treatment of persistent hypoparathyroidism. Given Yorvipath’s higher placebo-adjusted response rates of 52.9% at 4 weeks and 69% at 26 weeks in its clinical trials, UBS maintains that Ascendis Pharma’s medication continues to lead the hypoparathyroidism treatment space, despite supp ...